READ!!!: Abattis Bioceuticals Announces New CEO
Vancouver, British Columbia--(Newsfile Corp. - April 10, 2017) - Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis"), is pleased to announce the appointment of Robert Abenante as President and Chief Executive Officer of the Company.
Mr. Abenante is a seasoned executive with extensive public company experience. Mr. Abenante is a Chartered Professional Accountant (CPA, CA) who also holds a Masters. After his tenures with PricewaterhouseCoopers and Deloitte, Mr. Abenante founded and/or served as an officer/director of several public and private companies across various industries, ranging from energy and mining to agriculture technology and nutraceuticals.
"We are very excited to bring aboard someone with Mr. Abenante's high caliber skillset and impressive experience to lead our Company," states Rene David, the Company's CFO and Director. "His reputation for efficiently building management teams, cleaning up corporate structures and raising capital will drive growth in our Company both organically and through joint ventures, mergers and acquisitions."
After an extensive search, Abattis selected Mr. Abenante to lead the Company as its President and CEO. The timing is critical as the Company is targeting to launch its first lab in Langley, BC this month. The Company's subsidiary, Northern Vine Canada Inc. ("Northern Vine"), holds a controlled substances testing license issued by Health Canada. Northern Vine obtained the license after fulfilling Health Canada's rigorous specifications and successfully passing all its thorough inspections. Once the lab is opened, the Company will legally be able to test dried plant products, extracts, derivatives and edibles for licensed producers and patients under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR") regulatory framework. Although independent cannabis testing and analytical services are currently being used by some Licensed Producers under the ACMPR, the recently released "Report of the Task Force on Cannabis Legalization and Regulation" emphasized the importance of independent lab testing of all cannabis products. For more information about Northern Vine, see the Company website and below.
Mr. Abenante states, "I am very happy to be joining the Company, which is on the verge of attaining significant milestones in a rapidly evolving industry. Our focus in the short-term will be on opening our first lab and immediately beginning to grow our client base. We also have many late-stage products in our pipeline, ranging from CBD oils to Hemp drinks. Health sciences and nutraceuticals have long been a passion of mine, therefore, in addition to launching our lab and bringing late stage products to the market, I also intend to work with our talented professionals and scientists to reinvigorate our formulation and testing program so the Company can continue to bring innovative and cutting-edge products to the market through our Vergence division. It is my mission to raise the Company to the top of our industry through aggressive growth, both organically and through acquisitions, and my vision is to make significant positive contributions to the medical community through our research and development."
The Company's management and its Board of Directors are confident that Mr. Abenante's ability and experience will help add organizational structure to the team and unite it around a clear vision to achieve its ambitious growth targets. "We are all excited to rally around Mr. Abenante's vision and strategy to lead Abattis into becoming one of the premier companies in the cannabis sector," says Jim Irvine, a director of the Company.
AI
